Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.57
-3.07 (-1.46%)
AAPL  271.60
-2.63 (-0.96%)
AMD  204.57
-6.29 (-2.98%)
BAC  52.17
+0.48 (0.94%)
GOOG  303.96
-9.07 (-2.90%)
META  650.60
-3.09 (-0.47%)
MSFT  402.23
+1.63 (0.41%)
NVDA  186.65
-8.91 (-4.56%)
ORCL  148.08
+0.19 (0.13%)
TSLA  408.52
-8.88 (-2.13%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.